Tolerability of oral loading of divalproex sodium in the treatment of acute mania

James M. Martinez, James M. Russell, Robert M A Hirschfeld

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day. It is hypothesized that loading at this level will reach therapeutic levels of valproate more quickly, which in turn will decrease the latency of the therapeutic effect. Method: We conducted a retrospective chart review of all acutely manic patients admitted to our facility over a 12-month period. Those inpatients treated with initial divalproex sodium dosages of 30 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, were then included in the study. The serum valproate levels and daily Brief Psychiatric Rating Scale (BPRS) scores were documented for each subject. Any adverse changes in daily vital signs, serum liver enzymes, and blood cell counts were noted as well. Nursing and physician notes were then reviewed for any observed or reported adverse effects. Results: Twelve acutely manic inpatients were enrolled in the study. Three subjects did not complete the treatment and are not included in this analysis. The remaining nine subjects completed the treatment, bad a mean decrease in BPRS scores of 55.3%, and were discharged at least in partial remission. Six subjects bad serum valproate levels drawn within 48-72 b of the initial dose, with a mean valproate level of 95.5 mcg/ml. All nine subjects tolerated the treatment reasonably well, with one subject reporting sedation, one reporting sedation and constipation, and one reporting nausea, emesis, and urinary frequency. A transient, asymptomatic decrease in white blood cell count and a low granulocyte count were also noted in one subject. Conclusion: A divalproex dosage strategy beginning with 50 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, was reasonably well tolerated in this group of acutely manic patients, even with the concurrent use of other psychotropic medications. Blood levels of 56 to 124 mcg/ml were observed within 3 days after initating treatment.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalDepression and Anxiety
Volume7
Issue number2
DOIs
StatePublished - 1998

Fingerprint

Valproic Acid
Bipolar Disorder
Brief Psychiatric Rating Scale
Therapeutics
Inpatients
Serum
Blood Cell Count
Vital Signs
Therapeutic Uses
Constipation
Leukocyte Count
Granulocytes
Nausea
Vomiting
Nursing
Physicians
Safety
Liver
Enzymes

Keywords

  • Affective disorders
  • Affective symptoms
  • Bipolar disorder
  • Manic disorder
  • Psychopharmacology
  • Valproic acid

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Tolerability of oral loading of divalproex sodium in the treatment of acute mania. / Martinez, James M.; Russell, James M.; Hirschfeld, Robert M A.

In: Depression and Anxiety, Vol. 7, No. 2, 1998, p. 83-86.

Research output: Contribution to journalArticle

Martinez, James M. ; Russell, James M. ; Hirschfeld, Robert M A. / Tolerability of oral loading of divalproex sodium in the treatment of acute mania. In: Depression and Anxiety. 1998 ; Vol. 7, No. 2. pp. 83-86.
@article{4cf22c97f5f84d3788dfa1a9a2a52781,
title = "Tolerability of oral loading of divalproex sodium in the treatment of acute mania",
abstract = "Objective: To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day. It is hypothesized that loading at this level will reach therapeutic levels of valproate more quickly, which in turn will decrease the latency of the therapeutic effect. Method: We conducted a retrospective chart review of all acutely manic patients admitted to our facility over a 12-month period. Those inpatients treated with initial divalproex sodium dosages of 30 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, were then included in the study. The serum valproate levels and daily Brief Psychiatric Rating Scale (BPRS) scores were documented for each subject. Any adverse changes in daily vital signs, serum liver enzymes, and blood cell counts were noted as well. Nursing and physician notes were then reviewed for any observed or reported adverse effects. Results: Twelve acutely manic inpatients were enrolled in the study. Three subjects did not complete the treatment and are not included in this analysis. The remaining nine subjects completed the treatment, bad a mean decrease in BPRS scores of 55.3{\%}, and were discharged at least in partial remission. Six subjects bad serum valproate levels drawn within 48-72 b of the initial dose, with a mean valproate level of 95.5 mcg/ml. All nine subjects tolerated the treatment reasonably well, with one subject reporting sedation, one reporting sedation and constipation, and one reporting nausea, emesis, and urinary frequency. A transient, asymptomatic decrease in white blood cell count and a low granulocyte count were also noted in one subject. Conclusion: A divalproex dosage strategy beginning with 50 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, was reasonably well tolerated in this group of acutely manic patients, even with the concurrent use of other psychotropic medications. Blood levels of 56 to 124 mcg/ml were observed within 3 days after initating treatment.",
keywords = "Affective disorders, Affective symptoms, Bipolar disorder, Manic disorder, Psychopharmacology, Valproic acid",
author = "Martinez, {James M.} and Russell, {James M.} and Hirschfeld, {Robert M A}",
year = "1998",
doi = "10.1002/(SICI)1520-6394(1998)7:2<83::AID-DA6>3.0.CO;2-6",
language = "English (US)",
volume = "7",
pages = "83--86",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Tolerability of oral loading of divalproex sodium in the treatment of acute mania

AU - Martinez, James M.

AU - Russell, James M.

AU - Hirschfeld, Robert M A

PY - 1998

Y1 - 1998

N2 - Objective: To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day. It is hypothesized that loading at this level will reach therapeutic levels of valproate more quickly, which in turn will decrease the latency of the therapeutic effect. Method: We conducted a retrospective chart review of all acutely manic patients admitted to our facility over a 12-month period. Those inpatients treated with initial divalproex sodium dosages of 30 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, were then included in the study. The serum valproate levels and daily Brief Psychiatric Rating Scale (BPRS) scores were documented for each subject. Any adverse changes in daily vital signs, serum liver enzymes, and blood cell counts were noted as well. Nursing and physician notes were then reviewed for any observed or reported adverse effects. Results: Twelve acutely manic inpatients were enrolled in the study. Three subjects did not complete the treatment and are not included in this analysis. The remaining nine subjects completed the treatment, bad a mean decrease in BPRS scores of 55.3%, and were discharged at least in partial remission. Six subjects bad serum valproate levels drawn within 48-72 b of the initial dose, with a mean valproate level of 95.5 mcg/ml. All nine subjects tolerated the treatment reasonably well, with one subject reporting sedation, one reporting sedation and constipation, and one reporting nausea, emesis, and urinary frequency. A transient, asymptomatic decrease in white blood cell count and a low granulocyte count were also noted in one subject. Conclusion: A divalproex dosage strategy beginning with 50 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, was reasonably well tolerated in this group of acutely manic patients, even with the concurrent use of other psychotropic medications. Blood levels of 56 to 124 mcg/ml were observed within 3 days after initating treatment.

AB - Objective: To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day. It is hypothesized that loading at this level will reach therapeutic levels of valproate more quickly, which in turn will decrease the latency of the therapeutic effect. Method: We conducted a retrospective chart review of all acutely manic patients admitted to our facility over a 12-month period. Those inpatients treated with initial divalproex sodium dosages of 30 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, were then included in the study. The serum valproate levels and daily Brief Psychiatric Rating Scale (BPRS) scores were documented for each subject. Any adverse changes in daily vital signs, serum liver enzymes, and blood cell counts were noted as well. Nursing and physician notes were then reviewed for any observed or reported adverse effects. Results: Twelve acutely manic inpatients were enrolled in the study. Three subjects did not complete the treatment and are not included in this analysis. The remaining nine subjects completed the treatment, bad a mean decrease in BPRS scores of 55.3%, and were discharged at least in partial remission. Six subjects bad serum valproate levels drawn within 48-72 b of the initial dose, with a mean valproate level of 95.5 mcg/ml. All nine subjects tolerated the treatment reasonably well, with one subject reporting sedation, one reporting sedation and constipation, and one reporting nausea, emesis, and urinary frequency. A transient, asymptomatic decrease in white blood cell count and a low granulocyte count were also noted in one subject. Conclusion: A divalproex dosage strategy beginning with 50 mg/kg/day for 2 days, followed by 20 mg/kg/day thereafter, was reasonably well tolerated in this group of acutely manic patients, even with the concurrent use of other psychotropic medications. Blood levels of 56 to 124 mcg/ml were observed within 3 days after initating treatment.

KW - Affective disorders

KW - Affective symptoms

KW - Bipolar disorder

KW - Manic disorder

KW - Psychopharmacology

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=0031804744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031804744&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6394(1998)7:2<83::AID-DA6>3.0.CO;2-6

DO - 10.1002/(SICI)1520-6394(1998)7:2<83::AID-DA6>3.0.CO;2-6

M3 - Article

C2 - 9614597

AN - SCOPUS:0031804744

VL - 7

SP - 83

EP - 86

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 2

ER -